Powering Advancements
in Heart Health

The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health.

Simoa assays can detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers enables the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care. 

Latest News

We had the privilege of hosting a webinar led by Dr. Jennifer E. Van Eyk, professor of medicine at Cedars-Sinai Medical Center. Jennifer has been a long-time friend and supporter of Quanterix and we were honored to have her share her expertise with attendees. During the webinar, Dr.
View the recording of the panel discussion “Precision Cardiovascular Medicine: What is Different This Time” which took place at the World Medical Innovation Forum on May 2, 2017